Research programme: glucose transporter type 9 inhibitors - IOmet PharmaAlternative Names: GLUT-9 inhibitors - IOmet Pharma
Latest Information Update: 25 Jan 2016
At a glance
- Originator IOmet Pharma
- Mechanism of Action SLC2A9 protein inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Gout
Most Recent Events
- 11 Jan 2016 IOmet Pharma has been acquired by Merck & Co
- 10 Feb 2015 Early research in Gout in United Kingdom (unspecified route)